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Background: Histopathological evaluation method for predicting
the outcome of non-small cell lung cancer (NSCLC) treated by
neoadjuvant therapy has not been fully assessed. The purpose of this
study was to assess a novel histopathological evaluation method for
predicting the outcome of NSCLC treated by neoadjuvant therapy.
Methods: We reviewed the histopathology of the tumors of 53
NSCLC treated by neoadjuvant chemotherapy, chemoradiotherapy,
or radiotherapy followed by complete resection and identified the
histologic features produced by neoadjuvant therapy by comparing
them with the histologic features of the tumors in 138 NSCLC
cases treated by surgery without neoadjuvant therapy. We also
measured the area of residual tumor (ART) on the maximum cut
surface of the tumors and analyzed the relationships between the
histologic features, ART, and the outcome.
Results: The proportions of cases with the histologic features
“cholesterin clefts,” “foreign body reactive giant cells,” “stromal
hyalinosis,” and “bizarre nucleus in more than 50% of the cancer
cells” were significantly higher in the neoadjuvant therapy group
than in the surgery alone group. However, the presence of none of
these features had any significant effect on survival. Although
pathologic T factor and N factor had no significant effect on overall
survival, smaller ART (400 mm2) and absence of pleural invasion
(p []) were predictors of a outcome (p  0.014 and p  0.003,
respectively).
Conclusions: Smaller ART and p () predict a better outcome of
NSCLC treated by neoadjuvant therapy. We concluded that ART is
a novel histopathological evaluation method for predicting the
outcome of NSCLC treated by neoadjuvant therapy.
Key Words: Non-small cell lung cancer, Neoadjuvant therapy,
Histopathological evaluation method, Outcome, Histological fea-
tures, ART.
(J Thorac Oncol. 2010;5: 49–55)
Surgical resection is the standard treatment modality forstages I to III non-small cell lung cancer (NSCLC), but
many patients develop local and distant recurrence and die.
The 5-year survival rates for patients with NSCLC treated by
surgical resection have been disappointing, ranging from
67% for p-T1N0M0 to 23% for p-T1-3N2M0.1
Efforts to improve the survival of patients with resect-
able NSCLC and with potentially resectable more advanced
local disease have included the use of chemotherapy or
radiotherapy in postoperative (adjuvant) or preoperative (neo-
adjuvant) settings. Several trials in recent years, including in
large series of patients, have demonstrated the effectiveness
of adjuvant chemotherapy after complete resection.2–6 Al-
though several small randomized trials have reported neoad-
juvant therapy to be effective,7,8 because more recent studies
have failed to confirm their data,9,10 it remains a matter of
controversy. Interest in neoadjuvant therapy has been increas-
ing, because the efficacy of adjuvant therapy has been dem-
onstrated.
Histopathological evaluation methods for predicting
the outcome of NSCLC treated by neoadjuvant therapy have
not been fully assessed. Junker et al.11 used the following
histologic tumor regression grading system: grade I, no or
only slight tumor regression; grade IIA, marked but incom-
plete tumor regression, more than 10% vital tumor tissue;
grade IIB, less than 10% vital tumor tissue; grade III, com-
plete tumor regression without vital tumor tissue, and they
found that the grade of tumor regression is a significant
prognostic factor in NSCLC treated by neoadjuvant therapy.
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The survival rate of patients with grade IIB or III was
significantly better than the survival rate of patients with
grade I or IIA. However, it is difficult to calculate the ratio of
residual viable tumor tissue in the primary tumor, because
evaluation of primary tumor area before neoadjuvant therapy
is not over a level of the imagination. Moreover, the mor-
phologic definition of “viable cancer cells” is incongruous.
Because tumor cells persist in the form of islands in the
necrotic or fibrotic tissue, in some cases of NSCLC treated by
neoadjuvant therapy, measurement of tumor diameter is
sometimes difficult and does not always reflect residual tumor
size. Therefore, we tried to measure the area of residual tumor
(ART) on the maximum cut surface, and we analyzed the
correlations between several histologic features considered to
be attributable to neoadjuvant therapy, ART, and outcome.
In this study, we assess a more objective and reproduc-
ible histopathological evaluation method for predicting the
outcome of NSCLC treated by neoadjuvant therapy. Accurate
prognosis might serve as a guide to treatment after neoadju-
vant therapy and surgical resection.
PATIENTS AND METHODS
Patients
A series of 53 cases of NSCLC treated by neoadjuvant
chemotherapy, chemoradiotherapy, or radiotherapy followed
by complete resection in our hospital between July 1992 and
December 2006 were reviewed. The median follow-up period
of the 25 surviving patients was 42 months. The eight patients
who received neoadjuvant therapy followed by incomplete
resection and the eight patients who received neoadjuvant
therapy between January 2007 and February 2008 were also
included in the analysis of therapy-induced histologic fea-
tures. To define therapy-induced histologic features, 138
NSCLC cases in which surgery was performed without neo-
adjuvant therapy between January 2002 and December 2004
were also reviewed.
Pathologic Study
The surgically resected specimens from every case
were fixed with 10% formalin or absolute methyl alcohol and
embedded in paraffin. The tumors were cut into 5 to 10 mm
slices, and serial 4-m sections were stained with hematox-
ylin and eosin and by the Victoria van-Gieson method to
visualize elastic fibers. All slides containing the maximum
surface area of the tumor in each case were reviewed. Two
pathologists (Y.Y. and G.I.) reviewed the pathology under a
multiheaded microscope.
We examined the tumors for the presence of seven
histologic features referring to a past study given as fol-
lows11: (1) coagulation necrosis, necrosis in which tissue
becomes a dry, opaque, eosinophilic mass containing outlines
of anucleated cells; (2) foam cell infiltration, infiltration of
macrophages with foamy cytoplasm; (3) foam cell infiltration
around necrotic foci, the state that a foam cell infiltration
surrounds around necrotic foci; (4) cholesterin clefts, choles-
terin crystalloid bodies were present within cancer tissue; (5)
foreign body reactive giant cells, collections of fused macro-
phages (giant cell), which are generated in response to the
presence of a large foreign body; (6) stromal hyalinosis, the
formation of rounded masses or broad bands of homogeneous
acidophilic substances that have a glassy appearance; and (7)
bizarre nucleus in more than 50% of the cancer cells, the state
that more than 50% of the cancer cells have enlarged, irreg-
ular, or multiple nuclei (Figure 1). We considered these
histologic features to be positive when we found only a few
of them within cancer tissue.
We also measured the ART by the described method
below in all slides containing the maximum surface area of
the tumor.
We also evaluated pathologic T stage (ypT), pathologic
N stage (ypN), and pleural invasion. Pleural invasion was
defined as positive when tumor cells extended beyond the
elastic layer of the visceral pleura, which was stained blue
with Victoria van-Gieson stain.
Measurement of ART
We identified the residual tumor cells under a micro-
scope and outlined it on the slides with a marker pen (Figure
2A). Degenerated tumor cells containing a nucleus and cyto-
plasm were included as “residual tumor cells,” but necrotic
tumor cells were excluded. When a group of residual tumor
cells was 2 mm from the next group, we regarded it as a
FIGURE 1. Histologic features of non-small cell lung cancer
(NSCLC) treated by neoadjuvant therapy followed by surgi-
cal resection. (A) Coagulation necrosis, (B) foam cell infiltra-
tion, (C) foam cell infiltration around the necrotic foci, (D)
cholesterin clefts, the inset is a higher magnification of this
slide (foreign body reactive giant cells), (E) stromal hyalino-
sis, and (F) cancer cells containing a bizarre nucleus.
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separate group. We photographed the slides and traced the
areas marked in advance with image analysis software Win
ROOF version 5.0 (MITANI CORPORATION) (Figure 2B).
Statistical Analyses
We analyzed the correlations between the histologic
features and whether the patients had received neoadjuvant
therapy with Fisher’s exact test. We then analyzed the cor-
relations between the histologic features and the clinical
response with Fisher’s exact test.
We also analyzed the relationships between the histo-
logic features, the ART, ypT, ypN, and pleural invasion and
the outcome. These histopathological factors were entered
into univariate and multivariate analyses to determine
whether they had a significant effect on overall survival. The
survival rates were calculated by the Kaplan-Meier method,
and the differences were analyzed by means of the log-rank
test. The multivariate analysis was performed by means of
Cox’s proportional hazards model with commercial StatView
Version 5.0 statistical software (SAS Institute, Cary, NC).
RESULTS
Clinicopathological Characteristics of the
Patients Who Received Neoadjuvant Therapy
Table 1 shows the clinicopathological characteristics of
the patients who received neoadjuvant therapy. There were
42 men (79%) and 11 women (21%), and their median age
was 60 years (range: 32–74 years). The histologic type was
adenocarcinoma in 28 patients, squamous cell carcinoma in
17 patients, large cell carcinoma in four patients, adenosqua-
mous carcinoma in two patients, and pleomorphic carcinoma
in two patients. The histologic type in the six patients whose
resected specimen contained no residual vital tumor cells was
classified by histodiagnosis or cytodiagnosis of specimens
obtained by bronchoscopic or transcutaneous needle biopsy
before neoadjuvant therapy. Forty-two patients received che-
motherapy, 10 patients received chemoradiotherapy, and one
patient received radiotherapy before surgery. As neoadjuvant
chemotherapy, 17 patients had received mitomycin, vin-
desine, and cisplatin, and 19 patients had received some kind
of platinum-based combination chemotherapy, such as cis-
platin plus vindesine, cisplatin plus vinorelbine, cisplatin plus
docetaxcel, cisplatin plus gemcitabine, or carboplatin plus
FIGURE 2. Measurement of ART. A, We observed the area
of the residual tumor (ART) cells on slides under a micro-
scope and marked it with a marker pen. B, We photo-
graphed the slides and traced the areas that had been
marked with image analysis software (shown in yellow).
TABLE 1. Clinicopathological Characteristics of the
Patients Who Received Neoadjuvant Therapy (n  53)
Characteristic No. of Patients
Gender
Male/female 42/11
Age (yr)
Median (range) 60 (32–74)
Histology
Adenocarcinoma 28
Squamous cell carcinoma 17
Large cell carcinoma 4
Adenosquamous carcinoma 2
Pleomorphic carcinoma 2
Clinical stage
IA/IB/IIA/IIB/IIIA/IIIB/IV 0/10/0/18/16/4/5
c-T: T1/T2/T3/T4 1/18/29/5
c-N: N0/N1/N2/N3 29/9/13/2
Pathological stage
0/IA/IB/IIA/IIB/IIIA/IIIB/IV 6/4/10/1/13/12/7/0
yp-T: T0/T1/T2/T3/T4 6/6/17/17/7
yp-N: N0/N1/N2/N3 32/10/11/0
Neoadjuvant therapy
Chemotherapy 42
Chemotherapy  radiotherapy 10
Radiotherapy 1
Clinical response
Complete response 1
Partial response 27
Sable disease 22
Progressive disease 3
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paclitaxcel. Only four patients had received docetaxel alone,
and two patients had received gefitinib alone. The chemo-
therapy regimens with radiotherapy were mitomycin, vin-
desine, and cisplatin or cisplatin plus vinorelbine. The median
cycles of chemotherapy was two cycles (range: 1–4). The
median total dose of radiotherapy was 45 Gy (range: 28–50).
The clinical responses according to Response Evaluation
Criteria in Solid Tumors were a complete response (CR) in
one patient (2%), partial response (PR) in 27 patients (51%),
stable disease in 22 patients (42%), and progressive disease in
three patients (6%).
Histologic Features of NSCLC Treated with and
without Neoadjuvant Therapy
Table 2 compares the histologic features of NSCLC
according to whether the patients had received neoadjuvant
therapy. There were no significant differences in the rates of
“coagulation necrosis,” “foam cell infiltration,” or “foam cell
infiltration around necrotic foci.” “Bizarre nucleus in more
than 50% of the cancer cells,” “cholesterin clefts,” “foreign
body reactive giant cells,” and “stromal hyalinosis” were
observed in a significantly higher proportion of cases in the
neoadjuvant group than in the surgery alone group. We then
analyzed the correlations between these histologic features
and the clinical response, but no significant correlations were
found (Table 3).
The Prognostic Factors of NSCLC Treated by
Neoadjuvant Therapy
We analyzed the relationships between the histologic
features, the ART, ypT, ypN, and pleural invasion and the
outcome. Table 4 shows the results of the univariate analyses
of the prognostic factors of NSCLC treated by neoadjuvant
therapy. ART (400 mm2), and pleural invasion () were
significant prognostic factors for poorer overall survival (p 
0.014 and p  0.003, respectively). On the other hand,
“bizarre nucleus in more than 50% of the cancer cells,”
“cholesterin clefts,” “foreign body reactive giant cells,” “stro-
mal hyalinosis,” ypT, and ypN did not have any significant
prognostic value for overall survival. As shown in Table 5,
the multivariate analysis demonstrated pleural invasion ()
to be independent prognostic factor, and the hazard ratio was
3.600 (p  0.020). ART (400 mm2) showed a tendency for
poorer overall survival, and the hazard ratio was 2.063;
however, it was not significant poor prognosis factor (p 
0.079).
TABLE 2. The Comparison of Histological Features of
NSCLC According to Whether the Patients had Received
Neoadjuvant Therapy
Histological Feature
Neoadjuvant Therapy
p() N  69 (%) () N  138 (%)
Coagulation necrosis 47 (68) 91 (66) 0.875
Bizarre nucleus in
more than 50% of
the cancer cells
12 (17) 0 (0) 0.001
Cholesterin clefts 41 (59) 31 (22) 0.001
Foam cell infiltration 46 (67) 91 (66) 0.999
Foreign body reactive
giant cells
39 (57) 40 (29) 0.001
Stromal hyalinosis 46 (67) 37 (27) 0.001
Foam cell infiltration
around the necrotic
foci
21 (30) 35 (25) 0.507
NSCLC, non-small cell lung cancer.
TABLE 3. Histological Features and Clinical Response
Histological Feature CR  PR (n) SD  PD (n) p
Bizarre nucleus in more
than 50% of the cancer
cells
 5 7 0.533
 26 23
Cholesterin clefts  20 16 0.440
 11 14
Foreign body reactive
giant cells
 21 14 0.123
 10 16
Stromal hyalinosis  21 19 0.791
 10 11
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
TABLE 4. Univariate Analyses of the Prognostic Factors of
NSCLC Treated by Neoadjuvant Therapy (n  53)
Prognostic Factor n 5-Yr Survival (%) p
Histological features
Bizarre nuclei  11 48.5 0.532
 42 42.3
Cholesterin clefts  29 40.3 0.976
 24 47.4
Foreign body reactive
giant cells
 29 36.5 0.986
 24 50.0
Stromal hyalinosis  33 30.6 0.056
 20 64.3
ART 400 27 58.1 0.014
400 26 29.6
ypT T0–1 12 61.9 0.135
T2–4 41 39.5
ypN N0 32 54.6 0.119
N1–3 21 31.4
Pleural invasion  20 75.2 0.003
 33 28.3
Bizarre nuclei, Bizarre nucleus in more than 50% of the cancer cells; ART, the area
of residual tumor, NSCLC, non-small cell lung cancer.
TABLE 5. Multivariate Analyses of the Prognostic Factors
of NSCLC Treated by Neoadjuvant Therapy
Variable Hazard Ratio 95% CI p
ART 400 2.063 0.919–4.630 0.079
Pleural invasion () 3.600 1.221–10.614 0.020
CI, confidence interval; ART, the area of residual tumor.
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ART Predicts the Outcome of NSCLC Treated
by Neoadjuvant Therapy
Figures 3A, B show survival curves according to pleural
invasion, ART, respectively. We identified 27 patients with
an ART value 400 mm2 as a group of patients who had a
better outcome. The 5-year survival rate of those 27 patients
was 58.1% as opposed to 29.6% for the 26 patients in the
group whose ART value was 400 mm2 (Figure 3B). Fur-
thermore, the five patients with an ART value of 0 had
survived without recurrence, and the survival rate of the
group of 22 patients with ART value0 mm2 but400 mm2
was significantly higher than in the group the 26 patients with
ART values 400 mm2 (Figure 3C).
DISCUSSION
The degree of tumor regression based on the histo-
logic findings after neoadjuvant therapy has been consid-
ered an objective parameter and has been studied in pa-
tients with osteosarcoma,12 carcinoma of the prostate,13
esophagus,14 breast,15 and head and neck,16 gastric carci-
noma,17 and NSCLC.11 Several histologic features have
been considered to reflect tumor regression and the prog-
nosis. However, we found that the presence of some
histologic features in NSCLC including “coagulation ne-
crosis,” “foam cell infiltration,” and “foam cell infiltration
around necrotic foci” were unrelated to whether the patient
received neoadjuvant therapy. Other histologic features
including “bizarre nucleus in more than 50% of the cancer
cells,” “cholesterin clefts,” “foreign body reactive giant
cells,” and “stromal hyalinosis” were observed in higher
proportions of NSCLC treated by neoadjuvant therapy, but
there were no significant correlations between the presence
of these histologic features and clinical response, i.e.,
tumor reduction assessed radiographically. It has also been
reported that there is no association between clinical re-
sponse and histologic regression.18,19 Furthermore, these
histologic features were not related to a better outcome.
Junker et al.11 used their own grading system and
showed that the grade of therapy-induced tumor regression is
a significant prognostic factor in NSCLC. The same grading
system was used in our study, and the survival of the grade
IIB or III group was significantly better than in the grade I or
IIA group (5-year survival rate 62.2 versus 34.8%, p 0.031,
data not shown). Becker et al.17 used a similar grading system
and also reported finding that histologic tumor regression
grade was an objective measure of the effects of neoadjuvant
therapy in patients with gastric carcinoma and that it was
significantly correlated with survival. Mandard et al.14 used a
similar grading system and reported grade of tumor regres-
sion of esophageal carcinoma treated by neoadjuvant therapy
was strongly correlated with disease-free survival. Evaluation
of pathologically CRs (ART  0) is easy, and it is reported
that a pathologic CR predicts excellent survival in patients
with locally advanced NSCLC who receive neoadjuvant ther-
apy.20 However, it is sometimes difficult to determine the
ratio of residual viable tumor tissue in the primary tumor
tissue. We sometimes found that tumor cells remained in the
form of islands in the necrotic or fibrotic tissue, and it was
difficult to measure the size of tumors after neoadjuvant therapy,
and ypT does not always reflect residual tumor size or volume.
We found that ypT was not prognosis index in this study also.
Measuring ART can be used to overcome these problems.
Although ypT did not have any significant effect on
overall survival, ART predicted the outcome. We think it
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FIGURE 3. Overall survival curves
of the patients with non-small cell
lung cancer (NSCLC) who received
neoadjuvant therapy. Overall sur-
vival curves according to (A)
whether positive or negative for
pleural invasion, (B) whether ART
400 mm2 or 400 mm2, (C)
whether ART  0, ART 0 mm2
but ART 400 mm2, or 400
mm.2
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is because ypT does not always reflect residual tumor size.
Because tumor size reflects the prognosis of patients with
NSCLC who do not receive neoadjuvant therapy, it is
reasonable to think that ART reflects the prognosis of
patients with NSCLC who receive neoadjuvant therapy but
ypT does not.
Junker et al.18 found no correlation between clini-
cal response and survival. Our study had same findings
(5-year survival rate: CR  PR 47.8 versus SD  PR
34.9%, p  0.424). This observation suggests that patho-
logic assessment is of potentially greater utility in predict-
ing the patient’s prognosis whereas imaging studies may
be less useful.
Liu-Jarin et al.19 found a significantly higher rate of
response of patients with squamous cell carcinoma to neoad-
juvant chemotherapy compared with patients with adenocar-
cinoma, according to histologic tumor regression grade. Such
a finding could have important implications in the selection
criteria of patients with lung cancer to receive neoadjuvant
therapy. However, in this study, there was no correlation
between histologic type and histologic tumor regression
grade. The response rate of histologic tumor regression grade
was 28.5% (8 of 28) in adenocarcinoma and 29.4% (5 of 17)
in squamous cell carcinoma (p  0.951). When we show the
correlation between histologic tumor regression grade or
ART and the type of neoadjuvant therapy, the response rate
of histologic tumor regression grade was 16.6% (7 of 42) in
chemotherapy group and 100% (10 of 10) in chemoradiother-
apy group. The rate of patients with ART 400 mm2 was
42.8% (18 of 42) in chemotherapy group and 80% (8 of 10)
in chemoradiotherapy group.
We also tried measuring ARTmanually (manual ART) by
using a ruler to measure the perpendicular diameters of residual
tumor nests on all slides containing the maximum surface area of
the tumor. When the sum of the products of the perpendicular
diameters was used as the “manual ART” value, the group of
patients who had a manual ART value400 mm2 had a poorer
outcome (5-year survival rate 31.0% versus 60.8%, p  0.023,
data not shown). Therefore, manual measurements of ART can
also be used in clinical practice.
In this study, we also analyzed the relationship between
pleural invasion and outcome, because many cases with
pleural invasion were included in the study. Pleural invasion
was also found to be a significant prognostic factor for overall
survival and the multivariate analysis demonstrated pleural
invasion as independent prognostic factor. Pleural invasion
has been identified as a predictor of a poor outcome in
NSCLC,21 and we found that pleural invasion was also a
prognostic factor for NSCLC in patients who received neo-
adjuvant therapy.
In conclusion, we found that ART and pleural invasion
predict the outcome of NSCLC treated by neoadjuvant ther-
apy. We think that ART is a novel histopathological evalua-
tion method for predicting the outcome of NSCLC treated by
neoadjuvant therapy and that it can also serve as a guide to
treatment after surgical resection in patients who have re-
ceived neoadjuvant therapy.
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